Respiratory syncytial virus infection is a common illness affecting people of all ages, but it requires careful attention especially in the youngest and oldest patients. While most cases resolve with simple supportive measures, understanding the available preventive options and treatment approaches can help families and healthcare providers protect those most vulnerable to severe complications.

Managing RSV: From Comfort Care to Advanced Prevention

When someone develops a respiratory syncytial virus infection, the main goal of treatment is to help the body fight off the virus while managing symptoms that make breathing and daily activities difficult. Unlike bacterial infections that respond to antibiotics, RSV is caused by a virus, which means treatment focuses on supporting the patient through the illness rather than attacking the infection directly with medication.^[1]

The approach to treating RSV depends heavily on who is affected and how severe their symptoms are. For most healthy adults and older children, the infection behaves like a stubborn cold that clears up on its own within one to two weeks. However, infants under six months, premature babies, adults over 65, and people with chronic heart or lung conditions face a much higher risk of developing serious breathing problems that may require hospital care.^[2]

Treatment strategies have evolved significantly in recent years, particularly in the realm of prevention. While scientists have been working on an RSV vaccine for more than five decades following a failed vaccine trial in the 1960s, recent breakthroughs have finally brought effective preventive options to the market. Today’s treatment landscape includes both time-tested supportive care methods and cutting-edge immunization strategies designed to protect the most vulnerable before they ever encounter the virus.^[3]

Standard Treatment Approaches for Active RSV Infection

When someone is already sick with RSV, there is no specific antiviral medication that works reliably for most patients. The foundation of treatment is what doctors call supportive care—a collection of measures designed to help patients feel better and breathe easier while their immune system does the work of clearing the infection.^[9]

For patients managing RSV at home, treatment typically involves several straightforward interventions. Over-the-counter pain relievers such as acetaminophen (the active ingredient in Tylenol) can reduce fever and ease discomfort. However, there are important safety considerations: aspirin should never be given to children because it can cause a rare but serious condition, and cough medicine is not recommended for children under four years of age.^[10]

Maintaining adequate hydration—ensuring the patient drinks enough fluids—is critically important during RSV infection. The illness often reduces appetite, especially in infants who may struggle to feed, and fever increases fluid loss through sweating. Signs of dehydration (dangerous loss of body fluids) include a dry mouth, very little urine output, sunken eyes, and extreme fussiness or sleepiness. Parents should watch carefully for these warning signs, particularly in young babies.^[9]

Some healthcare providers may try a bronchodilator, a medication that opens up the airways by relaxing the muscles around them. These medicines, which include beta-agonist drugs, are commonly used for asthma. However, research has not clearly shown that bronchodilators help most children with RSV-related breathing problems. The American Academy of Pediatrics does not recommend their routine use for typical RSV bronchiolitis, though some doctors may offer a trial to see if an individual patient improves.^[15]

When RSV causes severe illness, hospitalization becomes necessary. In the United States, approximately two to three out of every 100 infants infected with RSV require hospital admission, with most being between two and six months old. Hospital treatment may include supplemental oxygen delivered through a mask or nasal prongs to help patients breathe more easily. Intravenous fluids may be given if a patient cannot drink enough on their own. In rare but serious cases, patients may need a breathing tube inserted into their airway and mechanical ventilation—a machine that helps them breathe.^[3][9]

One specific antiviral medication called ribavirin has been approved for treating severe RSV disease in children. Ribavirin works against many viruses in laboratory settings, and it is delivered as an aerosol (a mist that patients breathe in) using special equipment called a small-particle aerosol generator. The recommended treatment involves administering six grams of the drug in 300 milliliters of distilled water over 12 to 20 hours per day for three to seven days, depending on how the patient responds.^[15]

Despite being available for decades, ribavirin has not become a widely used treatment. Its high cost and the lack of clear evidence that it reduces hospitalization or death have limited its use. Additionally, there were concerns about potential risks to healthcare workers who might be exposed to the aerosolized drug, though such risks have never been proven. Today, ribavirin is primarily reserved for patients with serious underlying health conditions who develop severe RSV disease—such as children who have received organ transplants or who have severely weakened immune systems.^[13][15]

The duration of treatment for RSV varies depending on the patient and the severity of illness. Most people with mild symptoms feel better within one to two weeks, though a cough can persist for several weeks. Infants and young children who are hospitalized typically stay for just a few days as they receive supportive care and gradually improve.^[10]

Preventing Severe RSV: New Vaccines and Immunization Options

The most significant recent advances in RSV management have come in the area of prevention rather than treatment. After more than 50 years of research following a problematic vaccine trial in the 1960s that actually made RSV disease worse, scientists have finally succeeded in developing safe and effective immunizations to protect against severe RSV illness.^[12]

For pregnant women, there is now a vaccine called Abrysvo (also known as RSVpreF) that can be given between 32 and 36 weeks of pregnancy. When a pregnant person receives this vaccine during RSV season (typically from September through January), it helps protect their newborn baby from severe RSV illness during the first six months of life. Studies have shown that this maternal vaccination reduces the risk of RSV hospitalization in babies by 57% during this critical early period.^[4][22]

The maternal RSV vaccine is given only once. If a woman received the vaccine during any pregnancy, she should not get another dose in future pregnancies. Instead, babies born from later pregnancies should receive the immunization designed specifically for infants.^[22]

For babies and young children, there are preventive medicines available that work differently from traditional vaccines. These medications contain monoclonal antibodies—laboratory-made proteins that mimic the antibodies our immune system naturally produces to fight infections. One such medicine is Beyfortus (also called Nirsevimab), which is recommended by the Centers for Disease Control and Prevention for babies before or during their first RSV season. Another medicine called palivizumab has been used for many years, particularly for high-risk infants such as those born prematurely or those with chronic lung or heart disease.^[4][14]

It’s important to understand that these monoclonal antibody treatments are preventive measures—they help protect against severe RSV illness before it happens, but they cannot cure or treat children who already have RSV. They also cannot prevent an RSV infection entirely; rather, they reduce the risk that an infection will become serious enough to require hospitalization. Both medicines are given by injection (shots).^[4]

For older adults, three RSV vaccines have been approved for people aged 60 and older. Two vaccines—Arexvy (RSVPreF3 with a substance called AS01E that boosts immune response) and Abrysvo—were approved in June 2023. A third vaccine called mRESVIA (mRNA-1345), which uses the same messenger RNA technology as some COVID-19 vaccines, was approved in May 2024. These vaccines are recommended as a single lifetime dose for adults aged 75 and older, and for adults aged 50 to 74 who have certain chronic health conditions such as lung disease, heart disease, or weakened immune systems, or who live in nursing homes.^[6]

The decision to get an RSV vaccine involves a conversation between patients and their healthcare providers about individual risk factors and the benefits of immunization. For adults in the recommended age groups, getting the vaccine as soon as possible before RSV season begins offers the best protection against upcoming infections.^[6]

Investigational Approaches in Clinical Trials

While recent vaccine approvals represent major achievements, researchers continue to explore additional strategies for preventing and treating RSV. The research community has learned important lessons from past failures, particularly regarding a phenomenon called enhanced RSV disease that occurred in the 1960s vaccine trial. This knowledge has guided the development of safer approaches to RSV prevention.^[12]

Clinical trials are ongoing to test various strategies for preventing and treating RSV across different age groups. These trials typically progress through three main phases. Phase I trials focus primarily on safety, testing whether a new vaccine or treatment causes unacceptable side effects in small groups of people. Phase II trials expand to larger groups to assess whether the intervention actually works—whether a vaccine produces an immune response or whether a treatment improves symptoms. Phase III trials involve thousands of participants and compare the new intervention directly with existing treatments or placebos (inactive substances) to definitively prove effectiveness and safety before approval by regulatory agencies.^[12]

Beyond traditional vaccines, scientists are investigating innovative approaches such as long-acting monoclonal antibodies that could provide protection for entire RSV seasons with a single administration. Research is also exploring better antiviral medications that might work more effectively than ribavirin for treating active infections, particularly in high-risk patients such as those who have received organ transplants.^[13]

One area of particular interest is understanding the immunopathology of RSV—how the body’s own immune response to the virus contributes to lung damage and breathing problems. This knowledge could lead to treatments that calm harmful immune responses while still allowing the body to clear the infection. Researchers are also studying why some infants develop severe disease while others have only mild symptoms, which could eventually allow doctors to identify which babies need more intensive monitoring or preventive treatment.^[12]

Clinical trials for RSV treatments and vaccines are conducted in multiple countries, including the United States, Europe, and other regions around the world. Eligibility for these trials depends on many factors, including age, health status, and whether the trial is testing a preventive vaccine or a treatment for active infection. People interested in participating in RSV clinical trials can discuss options with their healthcare providers or search clinical trial registries to find studies recruiting participants in their area.

Most Common Treatment Methods

• Supportive Care at Home
  • Over-the-counter pain relievers like acetaminophen to reduce fever and discomfort (never aspirin in children)
  • Ensuring adequate fluid intake to prevent dehydration
  • Nasal saline drops and gentle suctioning to clear stuffy noses
  • Rest and monitoring for worsening symptoms
• Hospital Supportive Care
  • Supplemental oxygen delivered through masks or nasal prongs
  • Intravenous fluids for patients who cannot drink enough
  • Mechanical ventilation with breathing tubes in severe cases
  • Close monitoring of breathing, oxygen levels, and hydration status
• Preventive Immunizations
  • Maternal RSV vaccine (Abrysvo) given during pregnancy between 32-36 weeks
  • Monoclonal antibody treatments for infants (Beyfortus/Nirsevimab or palivizumab)
  • RSV vaccines for adults 60 and older (Arexvy, Abrysvo, or mRESVIA)
• Bronchodilator Trial
  • Beta-agonist medications that open airways, though evidence of benefit is limited
  • May be tried in selected cases with monitoring for response
  • Not routinely recommended for typical RSV bronchiolitis
• Antiviral Therapy
  • Ribavirin delivered as an aerosol for severe cases
  • Reserved primarily for immunocompromised patients or those with serious underlying conditions
  • Given over 3-7 days depending on clinical response